Pi-Cardia is a private, clinical stage medical device company developing a unique portfolio of non-implant-based solutions for treating heart valves. Pi-Cardia’s ShortCut™ device is designed to provide a safe, simple and effective way to split the leaflets of a pre-existing valve prior to transcatheter aortic valve replacement (TAVR) in patients at risk for coronary obstruction. ShortCut™ is currently being tested in a US pivotal clinical study.

Pi-Cardia’s Leaflex™ device mechanically scores valve calcification at multiple locations, with the intention of restoring leaflet flexibility and improving valve hemodynamics. Leaflex™ is designed to be a cost-effective, durable standalone treatment for patients with calcified aortic stenosis. Leaflex™ is being studies in global clinical trials.

Pi-Cardia’s leaflet modification technologies could further be used to expand treatment options in bicuspid and mitral valves.